New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

September 2018

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Results

Press Releases / By

Vyleesi™ New Tradename for Bremelanotide PDUFA Target Action Date of March 23, 2019 for Vyleesi Teleconference and Webcast to be held on September 13, 2018 CRANBURY, N.J., Sept. 13, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin …

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Results Read More »

Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2018 Results; Teleconference and Webcast to be held on September 13, 2018

Press Releases / By

Sep 07, 2018, 16:00 ET CRANBURY, N.J., Sept. 7, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2018 operating results on Thursday, September 13, 2018  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by …

Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2018 Results; Teleconference and Webcast to be held on September 13, 2018 Read More »

Scroll to Top